Molecular profiling and risk classification of patients with myeloproliferative neoplasms and splanchnic vein thromboses
Open Access
- 11 August 2020
- journal article
- research article
- Published by American Society of Hematology in Blood Advances
- Vol. 4 (15), 3708-3715
- https://doi.org/10.1182/bloodadvances.2020002414
Abstract
Myeloproliferative neoplasms (MPNs) are the most frequent underlying causes of splanchnic vein thromboses (SVTs). MPN patients with SVTs (MPN-SVT) often have a unique presentation including younger age, female predominance, and low Janus kinase 2 (JAK2) mutation allele burden. This study aimed at identifying risk factors for adverse hematologic outcomes in MPN-SVT patients. We performed a retrospective study of a fully characterized cohort of MPN-SVT patients. The primary outcome was the incidence of evolution to myelofibrosis, acute leukemia, or death. Eighty patients were included in the testing cohort. Median follow-up was 11 years. Most of the patients were women with a mean age of 42 years and a diagnosis of polycythemia vera. The primary outcome was met in 13% of the patients and was associated with a JAK2V617F allele burden >= 50% (odds ratio [OR], 14.7) and presence of additional mutations in genes affecting chromatin/spliceosome (OR, 9). We identified high-risk patients (29% of the cohort) as those harboring at least 1 molecular risk factor: JAK2-mutant allele burden >= 50%, presence of chromatin/spliceosome/TP53 mutation. High-risk patients had worse event-free survival (81% vs 100%; P = .001) and overall survival at 10 years (89% vs 100%; P = .01) than low-risk patients. These results were confirmed in an independent validation cohort of 30 MPN-SVT patients. In conclusion, molecular profiling identified MPN-SVT patients with dismal outcome. In this high-risk population, a disease-modifying therapy should be taken into consideration to minimize the probability of transformation.Keywords
This publication has 28 references indexed in Scilit:
- SomaticCALRMutations in Myeloproliferative Neoplasms with NonmutatedJAK2New England Journal of Medicine, 2013
- Somatic Mutations of Calreticulin in Myeloproliferative NeoplasmsNew England Journal of Medicine, 2013
- Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosisBlood, 2013
- Age-related differences in disease characteristics and clinical outcomes in polycythemia veraLeukemia & Lymphoma, 2013
- Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysisBlood, 2012
- Management of hepatic vascular diseasesJournal of Hepatology, 2012
- Gender and Vascular Complications in the JAK2 V617F-Positive Myeloproliferative NeoplasmsThrombosis, 2011
- A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)Blood, 2010
- The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 casesBlood, 2008
- A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia veraNature, 2005